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The effective therapeutic use of many small peptides uch as growth hormone has been limited by their small molecular 
masses and rapid clearance by the kidneys. Moreover, various degrees of nephrotoxicity have been reported for small 
proteins which are readily filtered at the level of the glomerulus. We have attempted to circumvent his drawback by 
conjugating rowth hormone (somatotropin) to serum albumin in an effort to alter the peptide’s pharmacokinetics while 
retaining its biological activity. 
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1. INTRODUCTION 
Small polypeptides with molecular masses in the 
order of 20000 Da have produced significant in- 
terest in recent years in terms of their therapeutic 
potential. Cytokines have been examined as anti- 
tumor agents due to their ability to stimulate the 
immune system, interferons are being examined as 
anti-viral agents, small enzymes such as tissue 
plasminogen activator (TPA) are being examined 
for their lytic activity and a wide variety of hor- 
mones are being tested for their therapeutic ef- 
ficacy in a range of clinical situations. This paper 
deals with growth hormone (GH), some of its 
clinical limitations and the possibility of cir- 
cumventing some of these by chemically cross- 
linking the hormone to homologous albumin. 
Human growth hormone (both native and 
genetically engineered) has been used for a number 
of years clinically for the stimulation of growth in 
children with growth hormone deficiencies [ 11. 
Results have been encouraging, but given the rapid 
clearance of the hormone and the fairly high 
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potential for immune reactivity, such hormone 
therapy is still considered a fairly experimental 
treatment. In the agriculture arena the possibility 
of administering growth hormone to cattle and 
swine has been widely considered [2]. This would 
lend itself not only to more rapid growth and 
weight gain but also to the production of a leaner 
animal as the growth hormone stimulates lipolysis. 
Several factors mitigate against the economic use 
of growth hormones in such instances. The rapid 
renal clearance of the peptide resulting in ac- 
cumulation in the kidney will have to be resolved 
before growth hormone and other similar peptides 
are used effectively. 
Our laboratory has for a number of years been 
involved in the use of albumin as a means of mak- 
ing enzymes more amendable for use in medicine. 
Our approach has been to conjugate enzymes to 
homologous albumin in an effort to: (i) stabilize 
the enzyme, (ii) alter the immunogenic nature of 
the enzyme, usually a foreign protein, and (iii) 
target the enzyme to specific tissue sites by the use 
of appropriately conjugated ligands [3,4]. In 
respect to the targeting issue, we have been suc- 
cessful in cross-linking insulin to either enzymes or 
to enzyme-albumin conjugates while retaining the 
insulin’s biological activity and its ability to bind 
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to and be internalized by its cell surface receptor 
[5]. We rationalize that if insulin can be con- 
jugated to albumin while retaining its biological 
activity then the same should be true of a number 
of other small peptide hormones. Conjugation 
might therefore be used to dramatically alter the 
pharmacokinetics and potential usefulness of ad- 
ministered hormones such as growth hormone. 
2. MATERIALS AND METHODS 
2.1. Preparation of growth hormone-albumin conjugates 
Porcine growth hormone was conjugated to either human or 
porcine serum albumin using glutaraldehyde as the cross- 
linking agent and using procedures [4] described for the con- 
jugation of insulin to either enzymes or enzyme-albumin 
polymers. 1 mg of porcine growth hormone was dissolved in 
1 ml of 50 mM PBS at pH 7.8. 1 mg of albumin in 3 ml of buf- 
fer was added with stirring at 4°C. 25 yl of 25% glutaraldehyde 
was added with stirring and the reaction allowed to proceed for 
3 h at which time the cross-linking was quenched by the addi- 
tion of 1 mg of glycine. The resultant mixture was dialyzed 
overnight against PBS (with 1% glycine) using dialysis tubing 
with a 35 kDa cut-off. The conjugate was purified by molecular 
sieve chromatography using Sephadex G-150. 
2.2. Lipolysis assay 
Lipolysis was measured according to described techniques [6] 
by determining glycerol production of tissue fragments of 
epididymal fat pads harvested from male Sprague Dawley rats. 
The tissue was incubated for 4 h in the presence or absence of 
varying concentrations of growth hormone or growth hormone- 
albumin conjugates. 
2.3. Insulin-like growth hormone activity 
Standard techniques [6] were used to determine the produc- 
tion of ‘?OZ from [%]glucose in the same adipose tissue 
preparation used for the lipolysis assay. The i4C02 was trapped 
using special tissue wells and 1 M hyamine hydroxide. 
2.4. In vivo experiments and blood urea nitrogen 
300-350 g male Sprague Dawley rats were anaesthetized us- 
ing i.p. ‘Somnotol’ or ‘Inactin’. Both femoral veins were can- 
nulated one for the injection of GH and the second for blood 
sampling. Blood samples were drawn at regular intervals. At 
various times the animals were killed and tissue samples assayed 
for ‘*?-albumin or ‘*%GH to determine tissue deposition of 
the GH or GH-albumin conjugates. 
Blood urea nitrogen assays were performed on 250 ~1 blood 
samples using a standard ‘Sigma’ BUN assay kit (no.535). 
3. RESULTS 
The data presented below is for porcine growth 
hormone (GH) in its free form or for a GH- 
albumin conjugate with a molecular mass of 
180 kDa representing a complex of, on average 
two molecules of albumin and”s’ix molecules of GH 
chemically cross-linked. Radiolabelled conjugates 
were prepared starting with ‘251-labelled GH and 
all conjugates were separated on Sephadex G150 to 
make sure that the preparation was free of non- 
conjugated GH. Fig.1 shows the elution profiles of 
free GH and purified GH-albumin conjugates. 
Fig.2 and table 1 examine the plasma clearance 
and tissue distribution of labelled GH and GH- 
albumin. The clearance rates for the free GH 
(ti,z = 5 min) is similar to that previously reported 
[7] and ‘fairly typical for small polypeptides that 
one would expect to be readily filtered by the 
glomerulus. The 180 kDa GH-albumin conjugate 
has an extended half life in the circulation of 
2-3 h. This appears to be primarily a function of 
size since 120 kDa conjugates of GH alone 
(similarly cross-linked) also have protracted cir- 
culation times (fig.2). The tissue deposition of the 
free GH indicates a rapid renal clearance and the 
appearance of a large fraction of the labelled GH 
in the urine. The GH-albumin clearly bypasses the 
kidneys and is cleared from the circulation largely 
by the liver. 
Tables 2 and 3 and fig.3 indicate that the con- 
jugated GH retains much of the activity of the 
native hormone and may show increased potency 
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Fig. 1. Molecular sieve chromatography of ‘“‘I-growth hormone 
(@--o) and ‘*‘I-growth hormone-albumin conjugates (%-%) 
on Sephadex G-150. The conjugate was prepared as described 
in the text, purified by column chromatography as described, 
stored for 72 h at 4°C and then rechromatographed. There is no 
evidence for any free growth hormone associated with the 
conjugate. Similarly in absorption data which is not shown, 
there is no evidence for any free albumin associated with the 
conjugate. 
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Fig.2. Plasma clearance of ‘25!-!abe!!ed free GH (C--O), GH- 
albumin conjugates (2/&) and GH-GH conjugates (NW---S). 
A!! animals received the equivalent amounts of growth 
hormone in the free or conjugated form. In each case the “‘1 
label is on the growth hormone but for the GH-albumin 
conjugate, identical results were obtained if the label was on the 
albumin or if the entire conjugate was labelled following the 
in the conjugated form. The conjugated form of 
GH is 2-10 times more active than the equivalent 
amount of free GH in terms of lipolysis (table 2) 
and glycerol release and in terms of insulin-like 
growth factor activity (table 3) and glucose utiliza- 
tion and CO2 release. 
Table 1 
% tissue distribution of ‘25!-labe!led growth hormone and 
growth hormone-albumin conjugates 
GH GH GH-Alb. GH-Alb. 
(5 min) (30 min) (30 min) (120 min) 
Blood (total) 30 5 72 45 
Heart 3 2 I 1 
Lungs 3 5 1 2 
Spleen 1 1 3 5 
Liver 4 2 8 22 
Kidneys 25 20 3 6 
Bladder (urine) 10 28 2 4 
Thyroid 1 1.5 0.5 1.5 
The values represent he means from 3 separated experiments 
calculated as a percentage of the tota! amount of radiolabel 
injected. Al! of the values have been corrected for the amount 
of label still present in the blood contaminating the particular 
organ. In each of the organs, including the blood, better than 
90% of the lz5! was found to be trichloroacetic acid 
precipitable. Values in brackets refer to the time (in min) when 
the animals were killed following the GH or GH-albumin 
administration 
Table 2 
Lipolytic activity of growth hormone and growth hormone- 
albumin conjugates 
were less than 5% for each set of determinations 
Preparation Glycerol 
(ngiml) @mo!/g per 60 min) 
0 7.81 
2.0 GH 8.98 
3.0 GH 9.14 
4.0 GH 10.97 
8.0 GH 15.11 
0.5 GH-albumin 9.55 
1 .O GH-albumin 13.80 
2.0 GH-albumin 14.98 
4.0 GH-albumin 16.08 
2.0 Albumin 8.01 
All values refer to rig/m!! of growth hormone whether it is in the 
free or the conjugated form. Each value represents the mean 
from 3 determinations of lipolytic activity. Standard deviations 
Fig.3 examines the in vivo effects of GH on 
nitrogen metabolism and blood urea nitrogen 
(BUN) levels in anaesthetized rats receiving various 
doses of GH in either free (fig.3a) or conjugated 
form (fig.3b). Surprisingly we found that the 
higher concentrations of free GH resulted in very 
Table 3 
Insulin-like growth hormone activity of free growth hormone 
and growth hormone-albumin conjugates 
Preparation ‘4co2 
(w/ml) (dpm/g per 60 min) 
OGH 5707 + 250 
100 GH 6150 f 140 
200 GH 7180 f 200 
400 GH 8560 f 285 
10 OH-albumin 6085 + 320 
50 GH-albumin 6850 f 180 
100 GH-albumin 8110 f 220 
200 GH-albumin 8430 + 250 
400 GH-albumin 8610 + 250 
100 albumin 5810 + 180 
Al! values refer to ng GH whether it is in the free or the 
conjugated form. Each value represents the mean and standard 
deviation from 3 determinations. The GH-albumin conjugate 
used in this experiment represents a different batch from that 
used in table 2 although each batch gave essentially similar data 
for both assays 
20 
Volume 239, number 1 FEBS LETTERS October 1988 
30- a Growth Hormone 
-0-o 
I 14 -x-‘x\& _ 
-n. 
10 - +-----b 
6* 
o I 2 3 4 5 6 7 6 
t (hl 
1st 
Growlh Hormone 
LAS Conlugate) 
.lOUQ 
0 5ouo 
. zooup 
* 5OOUQ 
0 1 2 3 4 5 6 7 6 
t (h1 
Fig.3. Blood urea nitrogen (BUN) levels in anaesthetized rats 
receiving various quantities of growth hormone in the free form 
(a) or equivalent amounts in the conjugated form (b). Values 
listed for amounts of growth hormone in b refer to the actual 
quantity of hormone and not the conjugate weight which is 
approximately double. Each point is the mean from 4 different 
rats. The standard deviations are in all cases 5% or less of the 
mean values. 
significant increases in BUN levels whereas only 
small amounts (10 and 20 pg) of GH resulted in the 
expected decrease in BUN levels indicative of 
growth stimulation and a more effective energy 
utilization, We suggest hat the increases in BUN 
levels seen for the higher concentrations of GH 
may be indicative of renal toxicity as large 
amounts of the free GH are filtered into the renal 
tubule [8,9]. On the other hand no such increases 
in BUN levels are observed when the rats were 
given similar amounts of GH conjugated with 
albumin (fig.3) where the decrease in BUN levels 
increased with the amount of GH-albumin ad- 
ministered. Evidence that nephrotoxicity was the 
explanation for the differences in BUN levels with 
free GH also comes from measuring serum 
creatinine levels’ (not shown) where levels rose only 
with higher concentrations of free GH and did not 
change for the smaller concentrations of GH or 
any of the concentrations of GH-albumin. (N.B. 
While lipolysis and insulin-like activities are 
demonstrated in vitro and nitrogen metabolism ap- 
pears altered in vivo, unpublished data from 
another laboratory suggests that the GH-albumin 
conjugate is not active in growth promotion in 
hypophysectomized rats.) 
4. DISCUSSION 
While an increased understanding of bioactive 
peptides and developments in protein and genetic 
engineering are making these compounds 
therapeutically attractive, there are serious limita- 
tions to their use in medicine as well as agriculture. 
We and others have noted the rapid clearance from 
the circulation of proteins with molecular masses 
of 20 kDa as well as the potential for renal toxicity 
when large amounts of protein are cleared to the 
renal tubule. The incidence of serious renal toxicity 
for other small peptides such as the cytokines has 
also been reported. 
This paper has demonstrated the possibility of 
altering small peptides by simple conjugation 
methods to larger molecules (such as homologous 
albumin) in the first instance to merely alter the 
pharmacokinetics by simply avoiding the kidneys. 
This has profound effects in terms of altered 
clearance, altered tissue deposition and reduced 
nephrotoxicity for GH and other bioactive pep- 
tides such as cytokines [lo]. The fact that so many 
of the activities of growth hormone are maintained 
is both fortuitous and of great interest; aithough 
the trial and error nature of the cross-linking pro- 
cedure required to find conditions to retain hor- 
mone activity should be emphasized. The fact that 
the GH activity appears higher in the conjugated 
form may reflect an allosteric synergy reported for 
insulin in the conjugated form by our laboratory 
[5] and by others [l 11. The fact that reports suggest 
that our compound does not stimulate growth in 
hypophysectomized rats is disappointing but does 
not detract from the observation that small active 
21 
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peptides may be engineered in such a way as to 
enhance their suitability as therapeutic agents. It 
may in fact reflect the multiple effects of GH [12] 
and the heterogeneity of GH receptors [13]. 
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